With $4.6B fund to spend, Blackstone branching beyond Clarus’ ‘bread and butter’ risk-sharing deals
Life sciences group seeking to own stakes in drugs, make growth-stage bets
The firm’s life sciences group is seeking to own stakes in commercial-stage drugs and make growth-stage bets.
Two years after Clarus’ acquisition by Blackstone, the life sciences investor is taking advantage of its parent company’s scale to stretch beyond its initial sweet spot. The firm that specialized in risk-sharing deals is now seeking to invest in products it can shepherd through to commercialization, as